MedTrace Logo

Gastrointestinal Motility in Patients With Neuroendocrine Tumors

NCT00789841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2010-10-26

No results posted yet for this study

Summary

We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects. For this we will use radio-opaque markers and the newly developed Motility Tracking System (MTS).

Hypothesis: Patients with NET and carcinoid syndrome have decreased GITT, gastric emptying and small bowel transit time and an increase in phase III MMC activity compared to healthy subjects. Treatment with somatostatin analogues increase transit times and decrease phase III MMC activity and improves the clinical symptoms.

Conditions

  • Neuroendocrine Tumor

Interventions

DEVICE

Magnetic Tracking System (MTS) and radio-opaque markers

MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • The Danish Medical Research Council

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00789841 on ClinicalTrials.gov